Intrinsic Value
Arcutis Biotherapeutics, Inc. · ARQT
Conservative
More adverse but historically defensible assumptions.
-$58,999.01
Base
The model's central intrinsic-value estimate.
-$92,354.85
Optimistic
More favorable but historically defensible assumptions.
-$138,493.52
Scenarios are the same model run under different but historically defensible assumptions. They are not price targets. Where a valuation gap is shown it is a comparison with a recent close, not a forecast return; where the price is stale, no gap is shown at all.
Model confidence: 53%Valuation as of Sep 21, 2026Latest filing used Feb 25, 2026
Confidence reflects data completeness, accounting quality, and model reliability. It is not a probability of future price.
Valuation drivers
- Normalized operating margin
- -107.7%
- Normalized NOPAT margin
- -85.1%
- Revenue growth
- 229.7%
- WACC
- 7.43%
- Terminal growth
- 2.50%
- Reinvestment method
- direct reinvestment
- Terminal-value share
- 84.0%
Model notes (5)
- Terminal value is 84% of enterprise value (Base case)
- Terminal value is 79% of enterprise value (Conservative case)
- Terminal value is 87% of enterprise value (Optimistic case)
- Minority interest not reported
- Preferred equity not reported
Model details
- Normalization
- V1
- Scenario
- V2
- Confidence
- V1
- Engine version
- valuation-1.0.1-share-units-terminal
- Data snapshot
- filed:2026-02-25